Background: Bevacizumab vials that are commercially available are fractionated into smaller quantities into the form of pre-filled syringes in a sterile and aseptic laboratory setting.
Purpose: To share the long term experience of aliquoting of bevacizumab injections in a tertiary eye care center in India.
Synopsis: Compounding of bevacizumab was found to be a cost-effective and sustainable practice that has benefited more patients with an affordable cost, while maintaining high levels of quality.
Highlights: Compounding of bevacizumab, when done with aseptic precautions can be a safe and cost-effective practice, the benefits of which can be passed on to needful patients.
Video Link: https://youtu.be/C5XOpKHFkew.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332976 | PMC |
| http://dx.doi.org/10.4103/ijo.IJO_1016_22 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk Factors, Clinical Characteristics, and Antibiotic Susceptibility Patterns of Keratitis: An 18-Year Retrospective Study from a Tertiary Hospital in China.
Antibiotics (Basel)
December 2024
Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing 100005, China.
Our aim was to investigate risk factors, clinical characteristics, and antibiotic susceptibility patterns of cornea-isolated species collected at a tertiary hospital in China over 18 years. This retrospective study reviewed data from 350 patients diagnosed with keratitis at Beijing Tongren Hospital between January 2006 and December 2023, including demographics, risk factors, clinical signs, in vivo confocal microscopy (IVCM) imaging, and antibiotic susceptibility testing. The predominant type was (n = 108, 29.
View Article and Find Full Text PDFPurpose: To report one-year real-world evidence on intraocular inflammation (IOI) adverse events (AEs) in patients undergoing faricimab therapy in a tertiary care hospital.
Methods: A retrospective review of electronic medical records was conducted for patients receiving faricimab treatment for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) at Moorfields Eye Hospital between September 1st, 2022, and August 31st, 2023. The primary outcome was the incidence of IOI (excluding endophthalmitis).
Terson Syndrome in Two Infants: Case Report and Literature Review.
Cureus
December 2024
Department of Ophthalmology, King Abdulaziz Medical City, National Guard Health Affairs, Riyadh, SAU.
Article Synopsis
- The report discusses two infants in Saudi Arabia diagnosed with Terson syndrome following traumatic head injuries.
- Both infants underwent pars plana vitrectomy (PPV) in an attempt to improve their vision.
- Unfortunately, both cases resulted in poor visual outcomes due to complications such as macular scars and retinal detachment.
Surgical Outcomes for Sensory Exotropia in a Tertiary Hospital in Manila, Philippines.
Acta Med Philipp
November 2024
Department of Ophthalmology and Visual Sciences, College of Medicine and Philippine General Hospital, University of the Philippines Manila, Manila, Philippines.
Background And Objective: There is no strict by-the-book rule as to which approach is the best strabismus surgery for patients with sensory exotropia. More commonly, a monocular lateral rectus recession and a medial rectus resection (monocular R & R; MRR) is performed in the eye with a poorer prognosis. Rarely, for larger deviations, a third or fourth horizontal muscle in the better eye is added.
View Article and Find Full Text PDFReal-World Results in Treating Diabetic Macular Edema With Faricimab at a London-Based Tertiary Eye Hospital.
Cureus
December 2024
Ophthalmology, Western Eye Hospital, Imperial College Healthcare NHS Trust, London, GBR.
Diabetic macular edema (DMO) poses a significant risk to vision, primarily caused by the leakage of retinal vessels. Traditional treatments involve anti-vascular endothelial growth factor (VEGF) agents and corticosteroids, though responses vary, necessitating frequent treatments. This retrospective study at a London-based tertiary eye hospital evaluates the efficacy of faricimab, a bispecific antibody inhibiting angiopoietin 2 (Ang-2) and VEGF-A, in treating DMO.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!